FATE Q4 2024 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+11.0% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$62M-3319.8% margin

Net Income

-$52M-2803.9% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-39.5%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$441M

Total Liabilities

$122M

Stockholders' Equity

$319M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+11.0%
Gross Profit	$2M	-$3M	+158.0%
Operating Income	-$62M	-$48M	-28.4%
Net Income	-$52M	-$44M	-18.2%